These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

705 related articles for article (PubMed ID: 9037338)

  • 41. Assessing the effectiveness of disease and injury prevention programs: costs and consequences.
    MMWR Recomm Rep; 1995 Aug; 44(RR-10):1-10. PubMed ID: 7565538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A cost-effectiveness analysis of a proposed national falls prevention program.
    Wu S; Keeler EB; Rubenstein LZ; Maglione MA; Shekelle PG
    Clin Geriatr Med; 2010 Nov; 26(4):751-66. PubMed ID: 20934620
    [TBL] [Abstract][Full Text] [Related]  

  • 43. WHO Guide for standardisation of economic evaluations of immunization programmes.
    Walker DG; Hutubessy R; Beutels P
    Vaccine; 2010 Mar; 28(11):2356-9. PubMed ID: 19567247
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Principles of cost-effectiveness research.
    Ganiats TG; Schneiderman LJ
    J Fam Pract; 1988 Jul; 27(1):77-84. PubMed ID: 3134508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Consumer-Operated Service Programs: monetary and donated costs and cost-effectiveness.
    Yates BT; Mannix D; Freed MC; Campbell J; Johnsen M; Jones K; Blyler CR
    Psychiatr Rehabil J; 2011; 35(2):91-9. PubMed ID: 22020838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methods for systematic reviews of economic evaluations for the Guide to Community Preventive Services. Task Force on Community Preventive Services.
    Carande-Kulis VG; Maciosek MV; Briss PA; Teutsch SM; Zaza S; Truman BI; Messonnier ML; Pappaioanou M; Harris JR; Fielding J
    Am J Prev Med; 2000 Jan; 18(1 Suppl):75-91. PubMed ID: 10806980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic evaluation of health services. Concepts and methodology applied to screening programmes.
    Griffiths DA
    Rev Epidemiol Sante Publique; 1981; 29(1):85-101. PubMed ID: 6789412
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An economic approach to clinical trial design and research priority-setting.
    Claxton K; Posnett J
    Health Econ; 1996; 5(6):513-24. PubMed ID: 9003938
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Superbugs: should antimicrobial resistance be included as a cost in economic evaluation?
    Coast J; Smith RD; Millar MR
    Health Econ; 1996; 5(3):217-26. PubMed ID: 8817296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opportunity costs and uncertainty in the economic evaluation of health care interventions.
    Sendi P; Gafni A; Birch S
    Health Econ; 2002 Jan; 11(1):23-31. PubMed ID: 11788979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis: what is it and how will it influence neurology.
    Holloway RG
    Ann Neurol; 1996 Jun; 39(6):818-23. PubMed ID: 8651658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic evaluation of osteoporosis prevention.
    Johannesson M; Jönsson B
    Health Policy; 1993 May; 24(2):103-24. PubMed ID: 10126753
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multivariate cost-effectiveness analysis: an application to optimizing ambulatory care for hypertension.
    Shepard DS; Stason WB; Perry HM; Carmen BA; Nagurney JT
    Inquiry; 1995; 32(3):320-31. PubMed ID: 7591045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health economic concepts, issues & challenges.
    Mukhopadhyay SP
    Indian J Public Health; 1994; 38(4):124-32. PubMed ID: 7797311
    [No Abstract]   [Full Text] [Related]  

  • 55. Exploring the role of economics in prioritization in public health: what do stakeholders think?
    Phillips CJ; Fordham R; Marsh K; Bertranou E; Davies S; Hale J; Kingsley M; Parke S; Porteous C; Rance J; Warm D
    Eur J Public Health; 2011 Oct; 21(5):578-84. PubMed ID: 20817687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A method to measure the costs of counseling for HIV prevention.
    Gorsky RD
    Public Health Rep; 1996; 111 Suppl 1(Suppl 1):115-22. PubMed ID: 8862166
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Economic analyses of health care. Cost benefit analyses promote better use of resources].
    Kristiansen IS
    Tidsskr Nor Laegeforen; 1990 Aug; 110(18):2377-81. PubMed ID: 2120789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcome studies in industry: cost-effectiveness of cumulative trauma disorder prevention.
    Mitchell CS
    Am J Ind Med; 1996 Jun; 29(6):689-96. PubMed ID: 8773729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A benefit-cost analysis of the Harlem hospital injury prevention program.
    Spicer RS; Miller TR; Durkin MS; Barlow B
    Inj Control Saf Promot; 2004 Mar; 11(1):55-7. PubMed ID: 14977506
    [No Abstract]   [Full Text] [Related]  

  • 60. Economic evaluations on cardiovascular preventive interventions in Argentina.
    Colantonio LD; Martí SG; Rubinstein AL
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):465-73. PubMed ID: 20715922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.